The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia

Hematology

Volumn 15, Issue 3, 2010, Pages 165-169

  Terasako, Kiriko ^a   Sato, Ken ^a   Sato, Miki ^a   Kimura, Shun Ichi ^a   Nakasone, Hideki ^a   Okuda, Shinya ^a   Kako, Shinichi ^a   Tanaka, Yukie ^a   Yamazaki, Rie ^a   Oshima, Kumi ^a   Tanihara, Aki ^a   Higuchi, Takakazu ^a   Nishida, Junji ^a   Kanda, Yoshinobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti thymocyte globulin; Cytomegalovirus; Graft versus host disease; Hematopoietic stem cell transplantation; Immune recovery

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE BODY RADIATION; ADOLESCENT; ANEMIA, APLASTIC; CHEMISTRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PROCEDURES;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77953566288     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X12583347113852     Document Type: Article

References (21)

1. Storb R, Blume KG, O'Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-44.
2. Champlin RE, Perez WS, Passweg JR et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109: 4582-4585.
3. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 2006; 34: 826-831.
4. Okuda S, Terasako K, Oshima K et al. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Am J Hematol 2009; 84: 167-169.
5. Deeg HJ, Amylon ID, Harris RE et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208-215.
6. Oshima K, Kanda Y, Nakasone H et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008; 83: 226-232.
7. Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689-692.
8. Asano-Mori Y, Kanda Y, Oshima K et al. Long-term ultra-lowdose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83: 472-476.
9. Asano-Mori Y, Kanda Y, Oshima K et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 2008; 87: 310-318.
10. Kanda Y, Mineishi S, Saito T et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 2002; 73: 568-572.
11. Thiede C, Florek M, Bornhauser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
12. Basara N, Baurmann H, Kolbe K et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005; 35: 1011-1018.
13. Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29-37.
14. Brennan DC, Flavin K, Lowell JA et al. A randomized, doubleblinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
15. Norrby J, Olausson M. A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplant Proc 1997; 29: 3135-3136.
16. Ourahma S, Talon D, Barrou B et al. A prospective study on efficacy and tolerance of antithymocyte globulin Fresenius versus thymoglobuline Merieux after renal transplantation. Transplant Proc 1997; 29: 2427.
17. Ducloux D, Kazory A, Challier B et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77: 1029-1033.
18. Kanda Y, Mineishi S, Nakai K et al. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood 2001; 97: 3676-3677.
19. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867-874.
20. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M et al. Highgrade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 813-819.
21. Kim HJ, Min WS, Cho BS et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704-717.